A place where evidence and action finally meet
For generations, the true scale of sexually transmitted infections across low- and middle-income countries has lived in fragments — buried in unpublished studies, scattered across journals, or simply absent from the record. This week, the World Health Organization brought those fragments together into a single open-access database, drawing on 766 studies and more than 2,400 data points to give health systems around the world a shared foundation of evidence. It is a quiet but consequential act: the transformation of scattered knowledge into a common resource, so that the distance between what is known and what can be done grows a little shorter.
- For decades, public health officials in low- and middle-income countries have been designing STI responses with incomplete maps — relying on estimates, borrowed data, or nothing at all.
- The WHO's new database consolidates 2,453 prevalence data points across five major STIs from 766 rigorously vetted studies, replacing fragmentation with a single, trustworthy source.
- The platform is fully open-access, meaning a community health worker in Lagos holds the same informational standing as a research institution in London — a deliberate leveling of the data landscape.
- Countries can now identify surveillance gaps, compare prevalence across age groups and risk populations, and allocate resources with a precision that guesswork never allowed.
- The database is built to expand — new STIs, new studies, and regular updates will keep it current, giving policymakers a living instrument rather than a static snapshot.
For the first time, the World Health Organization has assembled a single, searchable repository of sexually transmitted infection data — pulling together what was previously scattered across thousands of studies, locked behind paywalls, or sitting unpublished in filing cabinets across the globe. The result is something deceptively simple but genuinely consequential: a place where a public health official in Lagos or Lima can find the actual burden of chlamydia or gonorrhea in their region, drawn from rigorous research rather than guesswork.
The database covers five STIs — chlamydia, gonorrhea, herpes simplex virus type 2, syphilis, and trichomoniasis — drawing 2,453 distinct data points from 766 studies spanning more than a decade. Those studies were held to strict standards: clearly defined populations, solid methodology, samples drawn mostly from 2010 onward, and at least 100 participants each. The rigor matters. It means the numbers are not just numerous — they are trustworthy.
Dr. Tereza Kasaeva, who leads the WHO's department overseeing these diseases, described the launch as a watershed moment. Countries had long relied on estimates or data from other regions that might not reflect their own epidemiology. Now they have standardized, quality-assured information in one place — and because the platform is fully open-access, a nonprofit in a low-income country has the same reach as a well-funded institution in a wealthy one.
The platform is built to grow, with additional STIs and regular updates planned as new evidence emerges. What it offers, fundamentally, is a feedback loop: health ministries can now see how prevalence shifts across populations, identify gaps in their surveillance, and measure whether their interventions are working. That connection between evidence and action is how public health systems improve — and it now has a permanent address.
For the first time, the World Health Organization has built a single, searchable repository of sexually transmitted infection data—a database that pulls together what was previously scattered across thousands of studies, locked behind paywalls, or sitting unpublished in filing cabinets across the globe. The platform went live this week, and it represents something deceptively simple but genuinely consequential: a place where a public health official in Lagos or Lima can go to find out what the actual burden of chlamydia or gonorrhea looks like in their region, drawn from rigorous research rather than guesswork.
The database consolidates prevalence data on five sexually transmitted infections—chlamydia, gonorrhea, herpes simplex virus type 2, syphilis, and trichomoniasis—collected from 766 studies spanning more than a decade. Those studies contain 2,453 distinct data points, harvested from household surveys, clinics, pregnant women, adolescents, sex workers, and other populations at elevated risk. The WHO was deliberate about what made the cut. Each study had to clearly define its population, provide solid methodological detail, draw samples mostly from 2010 onward, and include at least 100 participants. That rigor matters. It means the numbers in the database are not just numerous—they are trustworthy.
Dr. Tereza Kasaeva, who heads the WHO's department overseeing HIV, tuberculosis, hepatitis, and sexually transmitted infections, framed the launch as a watershed moment. The database, she said, finally gives countries and their partners the evidence they need to design interventions that actually fit their populations, to build surveillance systems that catch trends early, and to measure progress against a disease burden that has long been difficult to quantify with precision. Before this, countries often had to rely on estimates or data from other regions that might not reflect their own epidemiology. Now they have access to standardized, quality-assured information in one place.
The platform is built to grow. The WHO plans to add more sexually transmitted infections as evidence accumulates and public health priorities shift. It will be updated regularly as new studies are published and vetted. The database is open-access, which means researchers, policymakers, national disease control programs, community organizations, and funding agencies can all draw from it without restriction. That democratization of data is itself significant. A nonprofit working in a low-income country has the same access as a well-funded research institution in a wealthy nation.
What the database does, fundamentally, is collapse the distance between evidence and action. A health ministry can now see not just whether chlamydia is a problem in their country, but how its prevalence compares across different age groups, settings, and risk populations. They can identify gaps in their surveillance. They can allocate resources more precisely. They can design programs that target the populations most affected. Over time, as the database grows and is updated, countries will be able to track whether their interventions are working—whether the prevalence they see today is moving in the direction they intended. That feedback loop, powered by better data, is how public health systems improve.
Citas Notables
This database represents a first major step forward in our ability to understand the burden of sexually transmitted infections across diverse populations and settings.— Dr. Tereza Kasaeva, WHO Director of the Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections
La Conversación del Hearth Otra perspectiva de la historia
Why does a centralized database matter so much? Countries have been tracking STIs for years.
They have, but not in any coordinated way. A researcher in one country might use different methods than someone in another. Studies get published in journals behind paywalls. Some findings never get published at all. So you end up with fragments—true fragments, but disconnected. A health ministry can't easily see the full picture of what's happening in their own region.
And now they can.
Now they can. They can see what the actual prevalence looks like in their population, compared to similar populations elsewhere. They can see which groups are most affected. That's the foundation for everything that comes next—targeting interventions, building surveillance, measuring whether you're making progress.
The database covers five STIs right now. Why not all of them?
Because the WHO only included studies that met strict quality standards. They wanted the data to be reliable. As more research gets done and published on other STIs, those will be added. It's designed to expand.
Who benefits most from this?
Countries with weaker surveillance systems, probably. A well-resourced health system might already have good data. But a ministry in a low- or middle-income country that's been flying somewhat blind—they suddenly have access to the same evidence base as anyone else. That's a real shift in power.
What happens next?
The database gets updated as new studies come in. The scope expands. And over time, countries start using it to actually change how they respond to STIs. That's when you'll know it worked.